A clinical trial assessing IBIO 600
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs IBIO-600 (Primary)
- Indications Obesity
- Focus Adverse reactions
- 28 Jan 2025 New trial record
- 02 Jan 2025 According to iBio media release, iBio expands cardiometabolic and obesity program with anti-myostatin antibody discovered using its proprietary platform, in-licensed from AstralBio, iBio plans to enter into clinical investigation in obesity and cardiometabolic disorders in 2026.